Lu sur https://www.ncbi.nlm.nih.gov/pubmed/28178923
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
Non-neuronal cholinergic activity is potentiated in myasthenia gravis.
Han B1, Zhang C1, Liu S2, Xia Y3, Sun H4, Gong Z5, Simard AR6, Liu Q1,7, Hao J8.
BMC Neurol. 2017 Feb 8;17(1):28. doi: 10.1186/s12883-016-0772-3.
Non-neuronal acetylcholine (ACh) restricts autoimmune responses and
attenuates inflammation by cholinergic anti-inflammation pathway. To date, the
implication of ACh in myasthenia gravis (MG) remained unexplored. This study
aimed to investigate the possible relationship between ACh levels,
anti-muscle-specific tyrosine kinase (MuSK) antibody titers, main clinical
features and outcomes of MG patients.
We successfully measured ACh levels in human peripheral blood
mononuclear cells (PBMCs) from 125 MG patients and 50 matched healthy controls by
using ultra-performance liquid chromatography-tandem mass spectrometry
(UPLC-MS/MS). We assessed the quantitative MG (QMG) scores for each patient and
titered anti-MuSK antibody.
We found that PBMC-derived ACh level was significantly higher in MG
patients, especially in patients of class III, IV-V, compared with that in
controls (0.142 ± 0.108 vs. 0.075 ± 0.014 ng/million cells, p = 0.0003) according
to the Myasthenia Gravis Foundation of America clinical classification.
Importantly, we also found that ACh levels were positively correlated with QMG
scores (r = 0.83, p < 0.0001) and anti-MuSK Ab levels (r = 0.85, p < 0.0001).
Our demonstration of elevated ACh levels in PBMCs of MG patients
foreshadows potential new avenues for MG research and treatment.